Assertio Holdings, Inc. (ASRT)
USD 0.62
(2.87%)
USD 0.62
(2.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -32.52 Million USD | -1783.7% |
| 2022 | 1.93 Million USD | -94.73% |
| 2021 | 36.68 Million USD | -42.06% |
| 2020 | 63.31 Million USD | -79.52% |
| 2019 | 309.15 Million USD | -32.08% |
| 2018 | 455.15 Million USD | -8.72% |
| 2017 | 498.64 Million USD | -7.89% |
| 2016 | 541.35 Million USD | -9.28% |
| 2015 | 596.74 Million USD | 277.33% |
| 2014 | -336.51 Million USD | -21.92% |
| 2013 | -276.01 Million USD | -254.36% |
| 2012 | -77.89 Million USD | -223.97% |
| 2011 | -24.04 Million USD | -18.11% |
| 2010 | -20.35 Million USD | 2.62% |
| 2009 | -20.9 Million USD | -60.85% |
| 2008 | -12.99 Million USD | 9.59% |
| 2007 | -14.37 Million USD | 1.37% |
| 2006 | -14.57 Million USD | -92.64% |
| 2005 | -7.56 Million USD | -180.21% |
| 2004 | 9.43 Million USD | 192.2% |
| 2003 | -10.23 Million USD | 4.49% |
| 2002 | -10.71 Million USD | -1201.15% |
| 2001 | 972.83 Thousand USD | 150.39% |
| 2000 | -1.93 Million USD | -437.0% |
| 1999 | -359.54 Thousand USD | 89.43% |
| 1998 | -3.4 Million USD | 17.07% |
| 1997 | -4.1 Million USD | -1466.67% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.08 Million USD | 89.78% |
| 2024 Q1 | -39.97 Million USD | -22.89% |
| 2023 Q4 | -32.52 Million USD | 14.45% |
| 2023 Q2 | -31.92 Million USD | -6.48% |
| 2023 FY | -32.52 Million USD | -1783.7% |
| 2023 Q3 | -38.02 Million USD | -19.1% |
| 2023 Q1 | -29.98 Million USD | -1651.86% |
| 2022 Q2 | 8.89 Million USD | -26.66% |
| 2022 Q4 | 1.93 Million USD | -42.0% |
| 2022 FY | 1.93 Million USD | -94.73% |
| 2022 Q3 | 3.33 Million USD | -62.56% |
| 2022 Q1 | 12.13 Million USD | -66.93% |
| 2021 Q3 | 19.94 Million USD | -18.76% |
| 2021 FY | 36.68 Million USD | -42.06% |
| 2021 Q4 | 36.68 Million USD | 83.96% |
| 2021 Q1 | 23.13 Million USD | -63.45% |
| 2021 Q2 | 24.54 Million USD | 6.08% |
| 2020 Q4 | 63.31 Million USD | 18.33% |
| 2020 Q1 | -48.1 Million USD | -115.56% |
| 2020 Q2 | 39.8 Million USD | 182.74% |
| 2020 Q3 | 53.5 Million USD | 34.43% |
| 2020 FY | 63.31 Million USD | -79.52% |
| 2019 Q1 | 434.33 Million USD | -4.58% |
| 2019 Q2 | 426.72 Million USD | -1.75% |
| 2019 Q4 | 309.15 Million USD | -0.72% |
| 2019 Q3 | 311.4 Million USD | -27.03% |
| 2019 FY | 309.15 Million USD | -32.08% |
| 2018 Q1 | 530.45 Million USD | 6.38% |
| 2018 FY | 455.15 Million USD | -8.72% |
| 2018 Q4 | 455.15 Million USD | -1.83% |
| 2018 Q3 | 463.62 Million USD | -11.32% |
| 2018 Q2 | 522.8 Million USD | -1.44% |
| 2017 Q2 | 516.32 Million USD | -3.6% |
| 2017 Q4 | 498.64 Million USD | -5.35% |
| 2017 FY | 498.64 Million USD | -7.89% |
| 2017 Q1 | 535.61 Million USD | -1.06% |
| 2017 Q3 | 526.8 Million USD | 2.03% |
| 2016 Q4 | 541.35 Million USD | -6.19% |
| 2016 Q3 | 577.09 Million USD | -7.21% |
| 2016 FY | 541.35 Million USD | -9.28% |
| 2016 Q1 | 622.58 Million USD | 4.33% |
| 2016 Q2 | 621.9 Million USD | -0.11% |
| 2015 Q4 | 596.74 Million USD | -14.15% |
| 2015 Q3 | 695.1 Million USD | 2.79% |
| 2015 Q2 | 676.27 Million USD | 275.14% |
| 2015 Q1 | 180.27 Million USD | 153.57% |
| 2015 FY | 596.74 Million USD | 277.33% |
| 2014 Q1 | -213.06 Million USD | 22.81% |
| 2014 Q2 | -211.14 Million USD | 0.9% |
| 2014 Q4 | -336.51 Million USD | -1.1% |
| 2014 FY | -336.51 Million USD | -21.92% |
| 2014 Q3 | -332.84 Million USD | -57.64% |
| 2013 Q1 | -21.93 Million USD | 71.85% |
| 2013 Q2 | -44.93 Million USD | -104.9% |
| 2013 Q3 | -64.28 Million USD | -43.06% |
| 2013 Q4 | -276.01 Million USD | -329.38% |
| 2013 FY | -276.01 Million USD | -254.36% |
| 2012 Q2 | -13.52 Million USD | 66.37% |
| 2012 FY | -77.89 Million USD | -223.97% |
| 2012 Q1 | -40.21 Million USD | -67.25% |
| 2012 Q4 | -77.89 Million USD | -184.57% |
| 2012 Q3 | -27.37 Million USD | -102.44% |
| 2011 Q2 | -36.19 Million USD | 56.23% |
| 2011 FY | -24.04 Million USD | -18.11% |
| 2011 Q3 | -19.94 Million USD | 44.89% |
| 2011 Q1 | -82.69 Million USD | -306.22% |
| 2011 Q4 | -24.04 Million USD | -20.55% |
| 2010 FY | -20.35 Million USD | 2.62% |
| 2010 Q4 | -20.35 Million USD | -19.21% |
| 2010 Q2 | -18.14 Million USD | -654.51% |
| 2010 Q3 | -17.07 Million USD | 5.9% |
| 2010 Q1 | -2.4 Million USD | 88.5% |
| 2009 Q4 | -20.9 Million USD | -92.4% |
| 2009 Q1 | -1.14 Million USD | 91.19% |
| 2009 Q3 | -10.86 Million USD | -1965.59% |
| 2009 Q2 | -526 Thousand USD | 54.06% |
| 2009 FY | -20.9 Million USD | -60.85% |
| 2008 Q4 | -12.99 Million USD | -159.92% |
| 2008 Q1 | -11.59 Million USD | 19.35% |
| 2008 FY | -12.99 Million USD | 9.59% |
| 2008 Q2 | -45.42 Million USD | -291.84% |
| 2008 Q3 | -5 Million USD | 88.99% |
| 2007 Q4 | -14.37 Million USD | -49.98% |
| 2007 FY | -14.37 Million USD | 1.37% |
| 2007 Q2 | -9.55 Million USD | -84.99% |
| 2007 Q3 | -9.58 Million USD | -0.31% |
| 2007 Q1 | -5.16 Million USD | 64.56% |
| 2006 Q4 | -14.57 Million USD | -430.3% |
| 2006 Q3 | -2.74 Million USD | 43.85% |
| 2006 FY | -14.57 Million USD | -92.64% |
| 2006 Q1 | -8.19 Million USD | -8.32% |
| 2006 Q2 | -4.89 Million USD | 40.27% |
| 2005 Q4 | -7.56 Million USD | 63.9% |
| 2005 Q2 | -1.05 Million USD | -606.73% |
| 2005 Q1 | 208.44 Thousand USD | -97.79% |
| 2005 FY | -7.56 Million USD | -180.21% |
| 2005 Q3 | -20.95 Million USD | -1884.33% |
| 2004 FY | 9.43 Million USD | 192.2% |
| 2004 Q2 | 8.08 Million USD | 413.49% |
| 2004 Q4 | 9.43 Million USD | 5.38% |
| 2004 Q3 | 8.95 Million USD | 10.76% |
| 2004 Q1 | -2.57 Million USD | 74.8% |
| 2003 Q4 | -10.23 Million USD | -252.06% |
| 2003 Q3 | 6.72 Million USD | 2682.23% |
| 2003 Q2 | 241.83 Thousand USD | -96.94% |
| 2003 Q1 | 7.89 Million USD | 173.71% |
| 2003 FY | -10.23 Million USD | 4.49% |
| 2002 Q2 | 3.78 Million USD | 238.85% |
| 2002 Q3 | -2.07 Million USD | -154.73% |
| 2002 Q4 | -10.71 Million USD | -416.97% |
| 2002 FY | -10.71 Million USD | -1201.15% |
| 2002 Q1 | -2.72 Million USD | -380.31% |
| 2001 Q2 | -3.67 Million USD | -151.06% |
| 2001 Q3 | 480.4 Thousand USD | 113.07% |
| 2001 Q4 | 972.83 Thousand USD | 102.5% |
| 2001 FY | 972.83 Thousand USD | 150.39% |
| 2001 Q1 | -1.46 Million USD | 24.15% |
| 2000 Q2 | -2.13 Million USD | 45.24% |
| 2000 Q3 | -1.53 Million USD | 28.1% |
| 2000 Q4 | -1.93 Million USD | -26.05% |
| 2000 FY | -1.93 Million USD | -437.0% |
| 2000 Q1 | -3.89 Million USD | -982.13% |
| 1999 Q1 | -2 Million USD | 41.18% |
| 1999 Q3 | -1.4 Million USD | 39.13% |
| 1999 Q4 | -359.54 Thousand USD | 74.32% |
| 1999 FY | -359.54 Thousand USD | 89.43% |
| 1999 Q2 | -2.3 Million USD | -15.0% |
| 1998 FY | -3.4 Million USD | 17.07% |
| 1998 Q1 | -10.8 Million USD | -163.41% |
| 1998 Q2 | -8.5 Million USD | 21.3% |
| 1998 Q4 | -3.4 Million USD | 44.26% |
| 1998 Q3 | -6.1 Million USD | 28.24% |
| 1997 Q3 | 1.2 Million USD | 0.0% |
| 1997 Q4 | -4.1 Million USD | -441.67% |
| 1997 FY | -4.1 Million USD | -1466.67% |
| 1996 FY | 300 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 1866.226% |
| Alpha Teknova, Inc. | 1.97 Million USD | 1747.872% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 134.529% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 143.401% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 107.472% |
| Cosmos Health Inc. | 8.59 Million USD | 478.651% |
| Journey Medical Corporation | -9.7 Million USD | -235.04% |
| Embecta Corp. | 1.31 Billion USD | 102.479% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 107.092% |
| Dynavax Technologies Corporation | 106.63 Million USD | 130.505% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 75.136% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 107.517% |
| PainReform Ltd. | -7.95 Million USD | -309.17% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -108.057% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -108.057% |
| SCYNEXIS, Inc. | -19.35 Million USD | -68.109% |
| Safety Shot Inc | -2.28 Million USD | -1323.978% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -244.962% |
| Procaps Group, S.A. | 242.93 Million USD | 113.39% |
| Theratechnologies Inc. | 24.87 Million USD | 230.791% |
| Harrow Health, Inc. | 116.41 Million USD | 127.942% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -1190.833% |
| Biofrontera Inc. | 4.05 Million USD | 901.997% |
| DURECT Corporation | -7.65 Million USD | -324.993% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 2.977% |
| Cronos Group Inc. | -663.32 Million USD | 95.096% |
| OptiNose, Inc. | 58.06 Million USD | 156.022% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 105.218% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -123.229% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -527.243% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 316.672% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -411.491% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 30541.048% |
| Radius Health, Inc. | 359.28 Million USD | 109.054% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 16594.683% |
| ProPhase Labs, Inc. | 19.23 Million USD | 269.149% |
| Phibro Animal Health Corporation | 454.84 Million USD | 107.152% |
| Procaps Group S.A. | 242.93 Million USD | 113.39% |
| Alvotech | 1.06 Billion USD | 103.056% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 984.421% |
| Viatris Inc. | 17.13 Billion USD | 100.19% |
| Rockwell Medical, Inc. | 4.45 Million USD | 830.004% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -566.988% |
| SIGA Technologies, Inc. | -148.68 Million USD | 78.122% |
| Tilray Brands, Inc. | 158.97 Million USD | 120.461% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 126.685% |
| Shineco, Inc. | 29.29 Million USD | 211.057% |
| PetIQ, Inc. | 351.93 Million USD | 109.243% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -1021.138% |
| Incannex Healthcare Limited | -5.48 Million USD | -493.054% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 118.347% |
| Alimera Sciences, Inc. | 55.3 Million USD | 158.813% |
| Silver Spike Investment Corp. | -32.61 Million USD | 0.253% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -2085.029% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -542.817% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -575.717% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -296.044% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 871.378% |
| Hempacco Co., Inc. | 13.61 Million USD | 338.926% |
| Talphera, Inc. | -5.72 Million USD | -468.589% |
| Alvotech | 1.06 Billion USD | 103.056% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 555.269% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 66.364% |
| Currenc Group, Inc. | -16.57 Million USD | -96.276% |
| Kamada Ltd. | -46.43 Million USD | 29.942% |
| Indivior PLC | -33.95 Million USD | 4.191% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 12583.594% |
| Flora Growth Corp. | -713 Thousand USD | -4462.272% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -296.044% |
| Evolus, Inc. | 63.7 Million USD | 151.06% |
| HUTCHMED (China) Limited | -197.45 Million USD | 83.526% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 106.789% |
| Akanda Corp. | 3.9 Million USD | 933.027% |